[ PAPER ] · 2017 · Journal of the American Medical Association (JAMA)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
R. Stupp, S. Taillibert, A. Kanner, W. Read, D. Steinberg, B. Lhermitte, S. Toms, A. Idbaih, M. Ahluwalia, K. Fink, F. Di Meco, F. Lieberman, Jay-Jiguang Zhu, G. Stragliotto, D. Tran, S. Brem, A. Hottinger, E. Kirson, G. Lavy-Shahaf, U. Weinberg, Chae-Yong Kim, S. Paek, G. Nicholas, Jordi Burna, H. Hirte, M. Weller, Y. Palti, M. Hegi, Z. Ram
Full narration with every figure explained. Generated once, shared with everyone.
[ TLDR ]
In the final analysis of this randomized clinical trial of patients with glioblastoma who had received standard radiochemotherapy, the addition of TTFields to maintenance temozolomide chemotherapy vs maintenance Temozolmide alone, resulted in statistically significant improvement in progression-free survival and overall survival.